Westlake Longevity Cohort

Aging Clinical Trial

— We-Longevity  

Official title:

Westlake Longevity Cohort

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05256251
• Other study ID #: 20211015ZJS001
• Status: Recruiting
• Start date: November 15, 2021
• Est. completion date: November 14, 2031

Study information

• Verified date: November 2023
• Source: Westlake University
• Contact: Ju-Sheng Zheng, PhD
• Phone: 86-0571-86915303
• Email: zhengjusheng[@]westlake.edu.cn
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The Westlake Longevity Cohort (We-Longevity) is a prospective cohort study among centenarians, nonagenarians, senior citizens and their family members up to three generations living in Lishui, China. The primary aim of this cohort is to characterize the multi-omics molecular characteristics of healthy longevity and their dynamic trajectories. Another aim of We-Longevity is to investigate the association of dietary and lifestyle with the multi-omics molecular characteristics of healthy longevity, and to facilitate the development of personalized nutritional/lifestyle recommendation for the public.

Description:

Aging is a major risk factor for most fatal diseases, such as Alzheimer's disease, type 2 diabetes, cardiovascular disease and cancer. Global population aging is becoming increasingly serious, and this trend is mainly driving the annual increase in the prevalence of aging-related diseases. Healthy longevity are influenced by a variety of factors, such as diet structure, lifestyle, ecological environment, gut microbiome and genetics. At present, the researches on healthy longevity are mainly focused on Drosophila, nematodes and mouse models, and few studies on longevity population. Centenarians and nonagenarians are the best objects to study healthy longevity. However, the multi-omics molecular characteristics and regulatory mechanism of healthy longevity in human are still unclear. There, the present We-Longevity design includes 200 centenarians, 600 nonagenarians, 400 senior citizens. We will determine the fecal/serum metabolome, gut microbiome serum proteome and genome, together with diet, lifestyle and disease information.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1200
• Est. completion date: November 14, 2031
• Est. primary completion date: November 14, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 50 Years and older

Eligibility

Inclusion Criteria:

• Participants aged 50 years or order.

• Participants live in Lishui, China.

• Participants intend to remain in Lishui for =3 years.

Exclusion Criteria:

• Participants with cancer, serious medical disorders or infectious diseases.

Related Conditions & MeSH terms

• Aging
• Alzheimer Disease
• Alzheimer's Disease
• Cardiometabolic Diseases
• Neurodegenerative Diseases

Locations

Country	Name	City	State
China	Lishui City People's Hospital	Lishui	Zhejiang

Sponsors (2)

Lead Sponsor	Collaborator
Westlake University	The Sixth Affiliated Hospital of Wenzhou Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	aging	Physical frailty will be evaluated by using Fried's criteria.	36 months
Primary	Gut microbiota	Fecal microbiome will be analyzed by 16S rRNA gene sequencing and metagenome sequencing.	36 months
Primary	Metabolomics of serum and gut microbiome	Metabolomics of serum and gut microbiome will be analyzed by liquid chromatograph-mass spectrometer (LC/MS).	36 months
Primary	Proteomic profiling of serum	Proteomic characterization of serum will be analyzed by liquid chromatograph-mass spectrometer (LC/MS).	36 months
Primary	Genome	Genomic characterization will be analyzed by Illumina ASA-750K arrays.	36 months
Secondary	Cognitive function	Cognitive function will be evaluated by using Mini-Mental State Examination (MMSE).	36 months
Secondary	Blood glucose examination of blood samples	Blood glucose will be analyzed by automatic biochemical analyser.	36 months
Secondary	Blood blood lipids examination of blood samples	Blood blood lipids (HDL, LDL, TC and TG) will be analyzed by automatic biochemical analyser.	36 months
Secondary	Serum cytokines examination of blood samples	Serum cytokines (IFN?, IL10, IL12p70, IL13, IL1ß, IL2, IL4, IL6, IL8 and TNFa) will be analyzed by electrochemiluminescence immunoassay.	36 months
Secondary	Serum neurotranszmitters examination of blood samples	Serum neurotranszmitters (dopamine, choline, acetyl choline, tyramine, tryptamine, 5-hydroxyindoleacetic acid, phenylpyruvic acid, 3,4-dihydroxyphenylacetic acid and 3-hydroxyo-aminobenzoic acid) will be analyzed by liquid chromatograph-mass spectrometer (LC/MS).	36 months